Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.54 |
| ▸ | CHRM4 known ✓ | P08173 | 5/20 | 0.54 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.54 |
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.54 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.54 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.35 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 3/20 | 0.39 |
| ▸ | CBX7 | O95931 | 2/20 | 0.39 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.39 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8067487 | 0.99 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8058738 | 0.87 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL3015716 | 0.82 | CD74 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8672170 | 0.80 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8065863 | 0.80 | CD74 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13215656 | 0.78 | CHRM2 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2223654 | 0.77 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8672653 | 0.77 | CHRM4 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8672717 | 0.77 | GABRA1 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL830500 | 0.76 | TNKS (0.51) | CHRM4CHRM5CHRM1TNKSHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344483-B1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-01 | — | — | EP | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-8299257-B2 | Compounds which have activity at M1receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20110178131-A1 | Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| EP-2344483-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2011-07-20 | — | — | EP | disclosed |
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| EP-2194983-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| EP-2194982-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010037723-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009037296-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210687-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 4/4885CHRM5 3/4885 |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 4/4885CHRM5 3/4885 |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 4/4885CHRM5 3/4885 |
| US-20110178131-A1 | Compounds Which Have Activity At M1 Receptor And Their Uses In Medicine | CHRM1, CHRM2, CHRM5 | CHRM2 2/4885CHRM4 4/4885CHRM5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.